Catalyst Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Catalyst Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 11.6% e 10.5% all'anno. Si prevede che l'EPS crescerà di 9.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 18% in 3 anni.

Informazioni chiave

11.6%

Tasso di crescita degli utili

9.14%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	23.6%
Tasso di crescita dei ricavi	10.5%
Rendimento futuro del capitale proprio	17.95%
Copertura analitica	Good
Ultimo aggiornamento	13 May 2025

Aggiornamenti recenti sulla crescita futura

Recent updates

Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely

Feb 21

We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease

Dec 19

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Nov 13

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Nov 07

Successful Product Expansions And Global Partnerships Fuel Revenue Surge And Profit Growth

Sep 10 Diversification and expansion strategies, including new product launches and international partnerships, contribute to financial stability and potential global revenue growth.

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CPRX - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	683	249	248	N/A	6
12/31/2026	610	222	242	309	8
12/31/2025	561	193	208	243	8
3/31/2025	535	197	268	268	N/A
12/31/2024	492	164	239	240	N/A
9/30/2024	460	143	186	225	N/A
6/30/2024	434	68	79	197	N/A
3/31/2024	411	65	46	163	N/A
12/31/2023	398	71	-136	144	N/A
9/30/2023	348	62	-114	128	N/A
6/30/2023	303	116	-48	124	N/A
3/31/2023	256	99	-53	120	N/A
12/31/2022	214	83	106	116	N/A
9/30/2022	192	67	85	95	N/A
6/30/2022	170	54	75	76	N/A
3/31/2022	154	45	65	65	N/A
12/31/2021	141	39	59	60	N/A
9/30/2021	134	42	53	54	N/A
6/30/2021	127	75	43	44	N/A
3/31/2021	120	72	41	42	N/A
12/31/2020	119	75	45	45	N/A
9/30/2020	118	71	44	44	N/A
6/30/2020	120	42	49	49	N/A
3/31/2020	119	43	50	50	N/A
12/31/2019	102	32	35	35	N/A
9/30/2019	73	9	14	14	N/A
6/30/2019	42	-12	-9	-9	N/A
3/31/2019	13	-29	-28	-28	N/A
12/31/2018	1	-34	N/A	-26	N/A
9/30/2018	N/A	-25	N/A	-22	N/A
6/30/2018	N/A	-21	N/A	-18	N/A
3/31/2018	N/A	-19	N/A	-16	N/A
12/31/2017	N/A	-18	N/A	-14	N/A
9/30/2017	N/A	-17	N/A	-14	N/A
6/30/2017	N/A	-17	N/A	-15	N/A
3/31/2017	N/A	-18	N/A	-16	N/A
12/31/2016	N/A	-18	N/A	-18	N/A
9/30/2016	N/A	-20	N/A	-18	N/A
6/30/2016	N/A	-20	N/A	-20	N/A
3/31/2016	N/A	-20	N/A	-20	N/A
12/31/2015	N/A	-20	N/A	-18	N/A
9/30/2015	N/A	-18	N/A	-17	N/A
6/30/2015	N/A	-18	N/A	-16	N/A
3/31/2015	N/A	-17	N/A	-14	N/A
12/31/2014	N/A	-16	N/A	-13	N/A
9/30/2014	N/A	-13	N/A	-13	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di CPRX ( 11.6% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di CPRX ( 11.6% all'anno) cresceranno più lentamente rispetto al mercato US ( 14.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di CPRX cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di CPRX ( 10.5% all'anno) crescerà più rapidamente del mercato US ( 8.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CPRX ( 10.5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di CPRX sarà basso tra 3 anni ( 18 %).

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/05/28 18:29
Prezzo dell'azione a fine giornata	2025/05/28 00:00
Guadagni	2025/03/31
Guadagni annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Catalyst Pharmaceuticals, Inc. è coperta da 18 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Joel Beatty	Baird
Jason Matthew Gerberry	BofA Global Research
Charles Duncan	Cantor Fitzgerald & Co.

Catalyst Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Catalyst Pharmaceuticals, Inc. Reaffirms Full-Year 2025 Revenue Outlook

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2025

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Consensus EPS estimates increase by 16%

Price target increased by 8.4% to US$29.57

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Recent updates

Chief Medical & Regulatory Officer notifies of intention to sell stock

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Reaffirms Full-Year 2025 Revenue Outlook

Catalyst Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 20, 2025

Investor sentiment improves as stock rises 15%

Executive VP & Chief Commercial Officer recently sold US$696k worth of stock

Insider notifies of intention to sell stock

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2025

Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely

Catalyst Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 26, 2025

Charles B. O’Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, Inc

Catalyst Pharmaceuticals, Inc. Announces Sub- Licensee DyDo Pharma Launches Firapse®? in Japan

Catalyst Pharmaceuticals and SERB S.A. Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease

Executive VP notifies of intention to sell stock

Co-Founder & Chairman notifies of intention to sell stock

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Successful Product Expansions And Global Partnerships Fuel Revenue Surge And Profit Growth

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Announces Management Changes, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case